Background: Compliance with dietary guidelines among pregnant women can positively influence not only their own health but also the health of their babies. Measuring the compliance requires professional skills in nutrition and dietary counseling. In China, few simple and effective techniques assess dietary quality among pregnant women, especially in rural areas. We aimed to establish a new simple and effective assessment technique, the “Chinese Dietary Guidelines Compliance Index for Pregnant Women (CDGCI-PW)” and assess the association between maternal dietary compliance and risks of pregnancy complications. Methods: The CDGCI-PW consists of 13 main components which were based on the 2016 edition of the Chinese dietary guidelines for pregnant women. Each component was assigned a different score range, and the overall score ranged from 0 to 100 points. The Tongji Maternal and Child Health Cohort study (from September 2013 to May 2016) was a prospective cohort study designed to examine maternal dietary and lifestyle effects on the health of pregnant women and their offspring. The maternal diet during the second trimester was compared with the corresponding recommended intake of the Chinese balanced dietary pagoda for pregnant women to verify their compliance with dietary guidelines. The association between maternal dietary quality and risks of pregnancy complications was estimated by regression analysis. Receiver operating characteristic (ROC) curves were constructed to identify the optimal cut-off values of CDGCI-PW for gestational hypertension and gestational diabetes mellitus (GDM). Results: Among the 2708 pregnant women, 1489 were eventually followed up. The mean CDGCI-PW score was 74.1 (standard deviation (SD) 7.5) in the second trimester. The majority of foods showed the following trend: the higher the CDGCI-PW score, the higher the proportion of pregnant women who reported food intake within the recommended range. Moreover, a higher maternal CDGCI-PW score was significantly associated with lower risks of gestational hypertension [odds ratio (OR) (95% confidence interval [(CI): 0.30 (0.20, 0.37)] and GDM [OR (95% CI): 0.38 (0.31, 0.48)]. The optimal CDGCI-PW cut-off value for gestational hypertension was ≥68.5 (sensitivity 82%; specificity: 61%; area under the ROC curve, AUC = 0.743), and the optimal CDGCI-PW cut-off score for GDM was ≥75.5 (sensitivity 43%; specificity: 81%; area under the ROC curve, AUC = 0.714). Conclusions: The CDGCI-PW is a simple and useful technique that assesses maternal diet quality during pregnancy, while adherence to the CDGCI-PW is associated with a lower risk of gestational hypertension and GDM.
Gestational diabetes mellitus (GDM) is a prevalent metabolic condition associated with pregnancy, defined by reduced glucose tolerance and insulin resistance (IR), which may have long-term consequences for both mother's and offspring's health.Recent evidence highlights the critical role of natural bioactive compounds, particularly anthocyanins—a group of flavonoid compounds abundant in berries—in regulating glucose metabolism and reducing GDM risk through their hypoglycemic, antioxidant, and anti-inflammatory properties. This review analyses the current knowledge about the effects of anthocyanins on glucose metabolism in the context of GDM. In vitro and in vivo studies suggest that anthocyanins enhance insulin sensitivity by promoting AMPK activation, increasing GLUT4 translocation, and lowering oxidative stress and proinflammatory cytokines, including TNF-α and IL-6. Moreover, anthocyanins inhibit the metabolic processes of α-glucosidase and α-amylase, thereby lowering postprandial hyperglycemia. Despite the lack of clinical research focused on GDM, preliminary trials including pregnant women predisposed to metabolic diseases indicate beneficial impacts on antioxidant capacity, lipid metabolism, and adipokine profiles. These findings indicate that anthocyanins may act as a beneficial supplement in the dietary control of GDM. Nevertheless, additional clinical trials are required to establish appropriate dosages, evaluate long-term safety, and validate their therapeutic efficacy during pregnancy.
Background: Gestational diabetes mellitus (GDM) is a pregnancy−related disorder characterized by inflammatory dysregulation that disrupts maternal–fetal immune homeostasis, yet the contribution of mitochondrial dysfunction to this pro−inflammatory state remains incompletely understood. Methods: This study combined transcriptomic data obtained from the GEO repository and mitochondrial gene lists from MitoCarta3.0 to pinpoint mitochondrial-related genes (Mito-RGs) exhibiting differential expression in GDM. Machine learning algorithms, including the least absolute shrinkage and selection operator (LASSO), random forest (RF), and extreme gradient boosting (XGBoost), were applied to identify hub Mito-RGs. Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) were performed to identify enriched pathways in various cell types. A predictive nomogram for GDM was developed based on Mito-RGs scores. Experimental validation was conducted in human placental tissues and a GDM mouse model to confirm hub gene expression. Results: DHRS2, STX17, and TIMM44 were identified as hub Mito-RGs involved in GDM. Scores based on these genes formed the basis of a nomogram with strong predictive performance for GDM. Single-cell RNA sequencing data indicated that GDM placental tissues exhibited higher proportions of epithelial cells, macrophages, and NK cells, alongside a significant reduction in tissue stem cells. Glycolysis and hypoxia-related pathways were enriched in epithelial and stem cells, whereas inflammatory and immune−activation pathways were predominantly enriched in macrophages, indicating pro−inflammatory remodeling of the placental immune microenvironment. Immunohistochemistry confirmed significantly elevated DHRS2 protein levels in placentas from GDM patients and GDM mouse models. Conclusions: These findings emphasize the critical impact of mitochondrial dysfunction on the pro−inflammatory reprogramming of the placental immune microenvironment in GDM, providing potential targets for anti−inflammatory and immunometabolic interventions.
Objectives: To explore whether metabolically healthy overweight (MHOW) and/or metabolically healthy obesity (MHO) increase hyperglycaemia risk in a Chinese population with a broad age range. Design: Retrospective cohort study. Setting: Secondary analysis of data from the DATADRYAD database, comprising health check records of participants from 32 regions and 11 cities in China between 2010 and 2016. Participants: A total of 47 391 metabolically healthy participants with none of the metabolic abnormalities were selected. Outcome measures: Hyperglycaemia includes incident diabetes and impaired fasting glucose (IFG). Diabetes was diagnosed with fasting blood glucose ≥7.0 mmol/L and typical clinical symptoms and/or on self-report during follow-up. The fasting plasma glucose level of IFG was from 5.6 to 6.9 mmol/L. Results: With an average follow-up of 3.06 years, 5274 participants (11.13%) developed hyperglycaemia over 144 804 person-years, with an incidence rate of 36.42 per 1000 person-years. Adjusted model revealed a higher risk of incident hyperglycaemia in the MHOW group (HR=1.23, 95% CIs 1.16 to 1.30) and the MHO group (HR=1.49, 95% CI 1.33 to 1.67) compared with the metabolically healthy normal weight group. With 1 unit increase of body mass index, the risk of hyperglycaemia increased by 6% (HR=1.06, 95% CI 1.04 to 1.07). The stratified analyses and interaction tests showed the robustness of the association, and there was a stronger association in women (p for interaction<0.001). Conclusions: The MHOW and MHO phenotypes were positively associated with a higher risk of hyperglycaemia in this population, and the association was particularly stronger in women.